The Use of IO Doublet in PD-L1-Negative NSCLC

David Carbone

2024 Intervention Selection & Sequencing in Early Stage NSCLC

Total Health

J. Porter

Year in Review: Lung Cancer

Balazs Halmos

ASCO® 2024 Lung Cancer Highlights: Top Abstracts Including BEAT-SC, …

2024 ASCO® Annual Meeting Insights Hub

B. Halmos

Updates in the Management of NSCLC: Systemic Therapy Year in Review

Total Health

W. Iams

Hyperprogression in Cancer Treated With Immunotherapy

Northwestern Medicine Oncology and Hematology

Y. Chae

Mediastinal Staging of Lung Cancer

MI&T Congressi

R. Trisolini

ASCO® 2023 Insights: "ADAURA Trial Key Learnings & Clinical Implicat…

Insights from 2023 ASCO® Annual Meeting

J. West

Metastatic EGFRm NSCLC: 1L Therapy Options

University of Colorado Cancer Center

T. Patil

Recent NSCLC Updates Including PAPILLON, CHECKMATE 77T, and KEYNOTE-…

ecancer

L. Raez

2024 Updates on the Fast-Changing NSCLC Landscape

Total Health

R. Osarogiagbon

ASCO® 2024 Lung Cancer Roundtable: Advances in NSCLC

ecancer

E. Felip, A. Spira, A. Passaro, A. Addeo

ESMO 2024 Summary: Management of Oligoprogressive Disease - Patients…

2024 ESMO Annual Meeting Insights Hub

R. Van den Begin

Year in Review: Precision Medicine

Vivek Subbiah

Duration of Immunotherapy Beyond 2 Years for Patients With Advanced …

IASLC Targeted Therapies of Lung Cancer 2023 Conference Coverage

E. Rodriguez

Multidisciplinary Panel Discussion: New Treatment Options for Surgic…

David Carbone

B. Stiles

Checkpoint Inhibitors, Arthritis and Other Autoimmune Triggers

West Virginia State Rheumatology Society

J. Bustamante

ASCO® 2024 Insights: "KRYSTAL-12 Study - Adagrasib vs. Docetaxel in …

2024 ASCO® Annual Meeting Insights Hub

T. Mok

Controversies in NSCLC: Neoadjuvant vs. Adjuvant IO in Early Stage D…

Luis Raez

PACIFIC Trial 5-Year OS Data: Clinical Implications in NSCLC

John Conibear